Research progress on the role of non-coding RNA in chemotherapy resistance of osteosarcoma
10.3760/cma.j.cn121113-20220825-00477
- VernacularTitle:非编码RNA在骨肉瘤化疗耐药中作用的研究进展
- Author:
Jiazhuang ZHU
1
;
Chunlin ZHANG
Author Information
1. 同济大学附属第十人民医院骨科，上海 200072
- Keywords:
Osteosarcoma;
Chemotherapy, adjuvant;
Drug resistance, neoplasm;
MicroRNAs;
RNA, Long noncoding;
RNA, circular
- From:
Chinese Journal of Orthopaedics
2023;43(13):922-927
- CountryChina
- Language:Chinese
-
Abstract:
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With the emergence of chemotherapy resistance in recent years, the survival rate of osteosarcoma patients has reached a bottleneck. Therefore, exploration of its chemoresistance mechanism is one of the popular research directions currently. Non-coding RNA (ncRNA) is a class of RNA without the ability to encode proteins, which is classified into microRNA, long non-coding RNA, and circular RNA based on length and shape. With the development of high-throughput sequencing technology, there is increasing evidence that some non-coding RNAs are abnormally upregulated or downregulated in osteosarcoma cells and affect the response of osteosarcoma to four commonly used chemotherapeutic drugs (methotrexate, doxorubicin, cisplatin and ifosfamide) through mechanisms such as regulation of apoptosis, cell cycle, signaling pathways, intracellular drug concentration, and cellular autophagy. Therefore, thesenon-coding RNAs are expected to be novel targets for osteosarcoma treatment. In this paper, the current studies were searched and reviewed on the above three non-coding RNAs mediating chemoresistance in osteosarcoma, aiming to provide a reference for breaking the bottleneck of survival rate of osteosarcoma patients.
